Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood Olsen, E. A., Whittaker, S., Willemze, R., Pinter-Brown, L., Foss, F. M., Geskin, L. J., Schwartz, L. H., Horwitz, S. M., Guitart, J., Zic, J., Kim, Y. H., Wood, G. S., Duvic, M., Ai, W. Z., Girardi, M., Gru, A., Guenova, E., Hodak, E., Hoppe, R. T., Kempf, W., Kim, E. J., Lechowicz, M. J., Ortiz-Romero, P. L., Papadavid, E., Quaglino, P., Pittelkow, M. R., Prince, H. M., Sanches, J. A., Sugaya, M., Vermeer, M. H., Zain, J., Knobler, R., Stadler, R., Bagot, M., Scarisbrick, J. J. 2021


The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sezary syndrome (MF/SS), the most common type of PCL, none exist for the other PCLs. In addition, staging in the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.

View details for DOI 10.1182/blood.2021012057

View details for PubMedID 34758074